To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC).
This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy received apatinib 250 mg per day until disease progression or unacceptable toxicity occurred. We analyzed the median progression-free survival (PFS), median overall survival (OS) and safety.
Of 23 enrolled patients, 1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95% CI 3.63–4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95% CI 7.20–9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95% CI 5.51–19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95% CI 9.86–24.14 months). The most frequent treatment-related adverse events were hand–foot syndrome (43.5%, 10/23) and secondary hypertension (30.4%, 7/23), followed by fatigue, proteinuria, nausea, and oral mucositis (17.4%, 13.0%, 13.0%, and 8.7%, respectively). Hematologic toxicity included thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). The main grade 3 or 4 toxicities were hand–foot syndrome (8.7%, 2/23) and hypertension (4.3%, 1/23).
Maintenance apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC.
Albain KS, Crowley JJ, Livingston RB (1991) Long-term survival and toxicity in small cell lung cancer expanded Southwest Oncology Group experience. Chest 99:1425–1432 CrossRef
Demedts I, Vermaelen K, Van Meerbeeck J (2010) Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 35:202–215 CrossRef
Hong W, Li H, Jin X, Shi X (2017) P1.07-053 apatinib for chemotherapy-refractory extensive stage SCLC: results from a single-center retrospective study. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2016.11.965
Kalemkerian GP et al (2013) Small cell lung cancer. J Natl Compr Cancer Netw 11:78–98 CrossRef
Leyvraz S et al (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for blood and marrow transplantation. J Clin Oncol 17:3531–3539 CrossRef
Li J et al (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529 CrossRef
Li J et al (2013) Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31:3219–3225 CrossRef
Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardio Thorac Surg 21:1105–1110 CrossRef
Masutani M et al (2000) Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol Rep 7:305–315
Noda K et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer New England. J Med 346:85–91
Pujol J-L et al (2015) Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 26:908–914 CrossRef
Ready NE et al (2015) Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study—CALGB 30504 (Alliance. J Clin Oncol 33:1660 CrossRef
Rossi A et al (2010) Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 70:119–128 CrossRef
Salven P, Ruotsalainen T, Mattson K, Joensuu H (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer International. J Cancer 79:144–146
Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114–2122 CrossRef
Sharma N et al (2014) Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Investig New Drugs 32:362–368 CrossRef
van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741–1755 CrossRef
Yang C, Ma L, Sun S, Cui H, Li Z, Cheng Y (2016) Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer. Zhonghua zhong liu za zhi (Chin J Oncol) 38:454–459
- Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II